drugset
Drugs / ISIS 3521
last change Sep 2002 re-read 3 minutes ago

ISIS 3521

also known as CGP 64128A

Antisense oligonucleotide targets PRKCA

Developed for
lung cancer · breast cancer · cutaneous melanoma
Investigated by
Eastern Cooperative Oncology Group · European Organisation for Research and Treatment of Cancer - EORTC · Ionis Pharmaceuticals, Inc. · National Cancer Institute (NCI)

Trials 3

today NCT00017407 · Ph 3 NCT00003236 · Ph 2 NCT00003989 · Ph 2
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT00003236 Jul 1998 → Jun 2002 breast cancer Eastern Cooperative Oncology Group Completed No outcome recorded
Phase 2 NCT00003989 Jun 1998 → ? cutaneous melanoma, lung cancer European Organisation for Research and Treatment of Cancer - EORTC Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00017407 Oct 2000 → Sep 2002 lung cancer Ionis Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as ISIS-3521 “ISIS-3521, An Antisense Inhibitor Of Protein Kinase C Alpha” NCT00017407 ↗
3

NCT00017407 ↗

NCT00003989 ↗

NCT00003236 ↗
Known as CGP 64128A “Randomized Phase II Study of Human C-raf Kinase Antisense Oligonucleotide Isis 5132 (CGP 69846A) or Human Pkc-Alpha Antisence Oligonucleotide ISIS 3521 (CGP 64128A) in Women...” NCT00003236 ↗
Action Inhibit “An Antisense Inhibitor Of Protein Kinase C Alpha” NCT00017407 ↗
Modality Antisense oligonucleotide “Human Pkc-Alpha Antisence Oligonucleotide ISIS 3521” NCT00003236 ↗
Route Intravenous “Patients receive ISIS 3521 IV continuously over 21 days.” NCT00003236 ↗
Target PRKCA “Human Pkc-Alpha Antisence Oligonucleotide ISIS 3521” NCT00003236 ↗